La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company (www.lajollapharmaceutical.com) is engaged in development and commercialization of therapies for patients suffering from life-threatening diseases. Its product pipeline include GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA (angiotensin II) injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. Its XERAVA (eravacycline) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. The Company's early-stage clinical development product candidate include TP-6076, TP-271, and TP-2846. Its TP-6076 is a IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia.

• La Jolla Pharmaceutical Company